Physician profile
Sandra Williams
NPI 1558397372
$4,132.25
in general payments reported to CMS, 2019-2025
32 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $733 · 2023: $1,126 · 2024: $1,206 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.20 | 2022-2025 | |
| Novo Nordisk INC | $572.49 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $332.08 | 2022-2025 | Mounjaro, Zepbound, Amyvid |
| Bayer Healthcare Pharmaceuticals INC. | $309.10 | 2022-2025 | |
| Amgen INC. | $240.84 | 2023-2025 | Otezla, Repatha, Otezla |
| Baxter Healthcare | $207.90 | 2022 | |
| Glaxosmithkline, LLC. | $180.07 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $176.49 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $151.46 | 2022 | |
| Exact Sciences Corporation | $138.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $127.50 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $105.95 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.00 | 2022-2024 | Spiriva Respimat, Stiolto Respimat, Synjardy |
| Merck Sharp & Dohme LLC | $81.12 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Insulet Corporation | $77.23 | 2022-2023 | Omnipod |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $73.61 | 2022-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.18 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $71.10 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $67.42 | 2023-2024 | Camzyos, Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.65 | 2024-2025 | Caplyta |
| Currax Pharmaceuticals LLC | $48.73 | 2023 | Contrave, Nexletol, Nexlizet |
| Ironwood Pharmaceuticals, INC | $48.25 | 2023-2024 | Linzess |
| Dexcom, INC. | $43.55 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $38.86 | 2024-2025 | Auvelity |
| Abbott Laboratories | $36.90 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $35.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.24 | 2025 | Rexulti |
| Lundbeck LLC | $22.68 | 2025 | Rexulti |
| Boston Scientific Corporation | $20.24 | 2025 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $15.73 | 2022 | |
| Alkermes, INC. | $15.44 | 2022 | |
| Tolmar, INC. | $13.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.